Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

– Manuscript further details findings from study assessing REL-1017 as adjunctive treatment for MDD

– Primary endpoint results included rapid, significant, and sustained efficacy vs. placebo 

– Safety analysis showed adverse event profile comparable to placebo, with no signs or symptoms of withdrawal or psychotomimetic effects associated with NMDAR blocking 

See more here